CoChat

Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials

Open access
Trinquart, Ludovic, Abbé, Adeline, Ravaud, Philippe · 2012 · PLoS ONE
Cited by 54

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Indirect comparisons of competing treatments by network meta-analysis (NMA) are increasingly in use. Reporting bias has received little attention in this context. We aimed to assess the impact of such bias in NMAs. METHODS: We used data from 74 FDA-registered placebo-controlled trials of 12 antidepressants and their 51 matching publications. For each dataset, NMA was used to estimate the effect sizes for 66 possible pair-wise comparisons of these drugs, the probabilities of being the best drug and ranking the drugs. To assess the impact of reporting bias, we compared the NMA results for the 51 published trials and those for the 74 FDA-registered trials. To assess how reporting bias affecting only one drug may affect the ranking of all drugs, we performed 12 different NMAs for hypothetical analysis. For each of these NMAs, we used published data for one drug and FDA data for the 11 other drugs. FINDINGS: Pair-wise effect sizes for drugs derived from the NMA of published data and those from the NMA of FDA data differed in absolute value by at least 100% in 30 of 66 pair-wise comparisons (45%). Depending on the dataset used, the top 3 agents differed, in composition and order. When reporting bias hypothetically affected only one drug, the affected drug ranked first in 5 of the 12 NMAs but second (n = 2), fourth (n = 1) or eighth (n = 2) in the NMA of the complete FDA network. CONCLUSIONS: In this particular network, reporting bias biased NMA-based estimates of treatments efficacy and modified ranking. The reporting bias effect in NMAs may differ from that in classical meta-analyses in that reporting bias affecting only one drug may affect the ranking of all drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0035219

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 28

  1. K Dickersin, 2010, Health-care policy. To reform U.S. health care, start with systematic reviews., Science, 329, 516, 10.1126/science.1189330 · DOI
  2. KG Volpp, 2009, Comparative effectiveness–thinking beyond medication A versus medication B., N Engl J Med, 361, 331, 10.1056/NEJMp0903496 · DOI · Paper page
  3. M Hochman, 2010, Characteristics of published comparative effectiveness studies of medications., JAMA, 303, 951, 10.1001/jama.2010.240 · DOI · Paper page
  4. DN Lathyris, 2010, Industry sponsorship and selection of comparators in randomized clinical trials., Eur J Clin Invest, 40, 172, 10.1111/j.1365-2362.2009.02240.x · DOI · Paper page
  5. C Estellat, 2012, Lack of Head-to-head Trials and Fair Control Arms: Randomized Controlled Trials of Biologic Treatment for Rheumatoid Arthritis., Arch Intern Med, 172, 237, 10.1001/archinternmed.2011.1209 · DOI · Paper page
  6. G Lu, 2004, Combination of direct and indirect evidence in mixed treatment comparisons., Stat Med, 23, 3105, 10.1002/sim.1875 · DOI · Paper page
  7. AM Glenny, 2005, Indirect comparisons of competing interventions., Health Technol Assess, 9, 1, 10.3310/hta9260 · DOI · Paper page
  8. F Song, 2009, Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews., BMJ, 338, b1147, 10.1136/bmj.b1147 · DOI · Paper page
  9. DM Kent, 2008, Stroke prevention–insights from incoherence., N Engl J Med, 359, 1287, 10.1056/NEJMe0806806 · DOI
  10. RS Stafford, 2009, New, but not improved? Incorporating comparative-effectiveness information into FDA labeling., N Engl J Med, 361, 1230, 10.1056/NEJMp0906490 · DOI
  11. D Eyding, 2010, Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials., BMJ, 341, c4737, 10.1136/bmj.c4737 · DOI · Paper page
  12. SS Vedula, 2009, Outcome reporting in industry-sponsored trials of gabapentin for off-label use., N Engl J Med, 361, 1963, 10.1056/NEJMsa0906126 · DOI · Paper page
  13. JP Higgins, 1996, Borrowing strength from external trials in a meta-analysis., Stat Med, 15, 2733, 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0 · DOI · Paper page
  14. NJ Welton, 2009, Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease., Am J Epidemiol, 169, 1158, 10.1093/aje/kwp014 · DOI · Paper page
  15. G Salanti, 2009, A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered., J Clin Epidemiol, 62, 857, 10.1016/j.jclinepi.2008.10.001 · DOI · Paper page
  16. E Turner, 2005, Correction/Clarification about FDA Review Documents., PLoS Med, 2, e422, 10.1371/journal.pmed.0020422 · doi:10.1371/journal.pmed.0020422
  17. JA Sterne, 2011, Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials., BMJ, 343, d4002, 10.1136/bmj.d4002 · DOI · Paper page
  18. SG Moreno, 2011, Adjusting for publication biases across similar interventions performed well when compared with gold standard data., J Clin Epidemiol, 64, 1230, 10.1016/j.jclinepi.2011.01.009 · DOI
  19. CD DeAngelis, 2010, Ensuring integrity in industry-sponsored research: primum non nocere, revisited., JAMA, 303, 1196, 10.1001/jama.2010.337 · DOI
  20. DA Zarin, 2008, Medicine. Moving toward transparency of clinical trials., Science, 319, 1340, 10.1126/science.1153632 · DOI · Paper page
  21. AB O'Connor, 2009, The Need for Improved Access to FDA Reviews., JAMA: The Journal of the American Medical Association, 302, 191, 10.1001/jama.2009.973 · DOI
  22. S Donegan, 2010, Indirect comparisons: a review of reporting and methodological quality., PLoS One, 5, e11054, 10.1371/journal.pone.0011054 · DOI · Paper page
  23. C O'Regan, 2009, Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison., Trials, 10, 86, 10.1186/1745-6215-10-86 · DOI · Paper page
  24. G Salanti, 2008, Exploring the geometry of treatment networks., Ann Intern Med, 148, 544, 10.7326/0003-4819-148-7-200804010-00011 · DOI · Paper page
  25. G Gartlehner, 2008, Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians., Ann Intern Med, 149, 734, 10.7326/0003-4819-149-10-200811180-00008 · DOI · Paper page
  26. I Chalmers, 2006, What are the implications of optimism bias in clinical research?, Lancet, 367, 449, 10.1016/S0140-6736(06)68153-1 · DOI
  27. EH Turner, 2004, A taxpayer-funded clinical trials registry and results database., PLoS Med, 1, e60, 10.1371/journal.pmed.0010060 · DOI · Paper page
  28. JD Miller, 2010, Registering Clinical Trial Results., JAMA: The Journal of the American Medical Association, 303, 773, 10.1001/jama.2010.207 · DOI

Cited by

See all 54

Metadata

Authors
Trinquart, L., Abbé, A., & Ravaud, P.
Venue
PLoS ONE
Published
2012-04-20
Volume
7
Issue
4
Pages
e35219
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2038645302
Cited by
54
References
16
FWCI
2.95
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials. https://app.cochat.ai/papers/10.1371/journal.pone.0035219
The paper
Trinquart, L., Abbé, A., & Ravaud, P. (2012). Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials. PLoS ONE. https://doi.org/10.1371/journal.pone.0035219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.